SIMCERE PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.97 HKD | -1.81% |
|
+1.88% | -11.29% |
| Jun. 03 | Simcere Pharmaceutical’s Cancer Drug Shows Positive Results | MT |
| Jun. 03 | Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,011 | 3,031 | 3,958 | 2,255 | 1,946 | - | - |
| Enterprise Value (EV) 2 | 3,016 | 2,945 | 3,796 | 2,173 | 1,666 | 1,579 | 1,505 |
| P/E ratio | 26.9 x | 12.6 x | 28.5 x | 22.7 x | 14.2 x | 11.1 x | 9.62 x |
| Yield | 1.99% | 2.05% | 1.56% | 2.62% | 2.45% | 3.05% | 3.44% |
| Capitalization / Revenue | 4.37 x | 3.86 x | 4.3 x | 2.46 x | 1.88 x | 1.62 x | 1.42 x |
| EV / Revenue | 4.38 x | 3.75 x | 4.13 x | 2.37 x | 1.61 x | 1.32 x | 1.1 x |
| EV / EBITDA | 27.9 x | 11 x | 24 x | 15.3 x | 8.8 x | 6.71 x | 5.35 x |
| EV / FCF | - | -46.9 x | - | - | 16.1 x | 15.1 x | 11.9 x |
| FCF Yield | - | -2.13% | - | - | 6.23% | 6.61% | 8.38% |
| Price to Book | 3.4 x | 2.97 x | 3.83 x | 2.21 x | 1.84 x | 1.64 x | 1.45 x |
| Nbr of stocks (in thousands) | 2,608,642 | 2,628,291 | 2,660,377 | 2,616,723 | 2,546,090 | - | - |
| Reference price 3 | 7.533 | 7.325 | 10.26 | 6.117 | 5.538 | 5.538 | 5.538 |
| Announcement Date | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1CNY in Million2USD in Million3CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 746.6 | 688.7 | 785.2 | 919.9 | 917.9 | 1,032 | 1,200 | 1,372 |
| EBITDA 1 | - | 108 | 267 | 158.1 | 141.9 | 189.2 | 235.2 | 281 |
| EBIT 1 | - | 74.08 | 178.1 | 125.6 | 98.87 | 139.9 | 188.1 | 237.1 |
| Operating Margin | - | 10.76% | 22.68% | 13.65% | 10.77% | 13.55% | 15.68% | 17.29% |
| Earnings before Tax (EBT) 1 | - | 123 | 220.1 | 129.3 | 102.8 | 143.5 | 192.5 | 244.4 |
| Net income 1 | 148.8 | 102.3 | 236.7 | 135.8 | 99.28 | 140.5 | 179.7 | 208.6 |
| Net margin | 19.93% | 14.85% | 30.14% | 14.76% | 10.82% | 13.61% | 14.98% | 15.21% |
| EPS 2 | - | 0.2800 | 0.5800 | 0.3600 | 0.2700 | 0.3888 | 0.4976 | 0.5756 |
| Free Cash Flow 1 | - | - | -62.76 | - | - | 103.7 | 104.5 | 126 |
| FCF margin | - | - | -7.99% | - | - | 10.05% | 8.71% | 9.19% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 54.81% | 44.42% | 44.85% |
| FCF Conversion (Net income) | - | - | - | - | - | 73.83% | 58.13% | 60.42% |
| Dividend per Share 2 | - | 0.1500 | 0.1500 | 0.1600 | 0.1600 | 0.1360 | 0.1691 | 0.1906 |
| Announcement Date | 10/12/20 | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1USD in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 |
|---|---|---|
| Net sales 1 | - | 448.4 |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 312.5 | - |
| Net margin | - | - |
| EPS | 0.8600 | - |
| Dividend per Share | - | - |
| Announcement Date | 8/21/23 | 3/20/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4.55 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 86 | 162 | 81.8 | 280 | 366 | 441 |
| Leverage (Debt/EBITDA) | - | 0.0421 x | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -62.8 | - | - | 104 | 104 | 126 |
| ROE (net income / shareholders' equity) | - | 19.7% | 25.7% | 13.8% | 9.96% | 12.4% | 14.7% | 15.8% |
| ROA (Net income/ Total Assets) | - | 7.56% | 14.3% | 8.91% | 6.61% | 8.39% | 10.1% | 11.1% |
| Assets 1 | - | 1,353 | 1,657 | 1,524 | 1,503 | 1,675 | 1,782 | 1,876 |
| Book Value Per Share 2 | - | 2.220 | 2.470 | 2.680 | 2.770 | 3.010 | 3.370 | 3.830 |
| Cash Flow per Share 2 | - | 0.0400 | -0.0800 | 0.5200 | - | 0.2400 | 0.3900 | - |
| Capex 1 | - | 54.4 | 32 | 49.9 | - | 84.7 | 82.4 | 88.9 |
| Capex / Sales | - | 7.9% | 4.07% | 5.43% | - | 8.2% | 6.87% | 6.48% |
| Announcement Date | 10/12/20 | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1USD in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.538
CNY
Average target price
7.984
CNY
Spread / Average Target
+44.16%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.29% | 1.95B | |
| +19.64% | 43.3B | |
| +21.25% | 22.22B | |
| +18.92% | 15.43B | |
| +20.14% | 14.48B | |
| +53.19% | 12.72B | |
| -0.05% | 6.79B | |
| -11.11% | 6.71B | |
| -8.87% | 5.73B | |
| +14.68% | 5.5B |
- Stock Market
- Equities
- 2096 Stock
- Financials Simcere Pharmaceutical Group Limited
